# Semaglutide

## Ozempic inj 4mg/3mL

| TAH Drug Code      | [IOZE4](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IOZE4)                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Type 2 diabetes mellitus. Prophylaxis of disorder of cardiovascular system with type 2 diabetes mellitus.                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | SC, 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly; may increase to maximum 1 mg once weekly if additional glycemic control is needed after at least 4 weeks of the 0.5 mg weekly dosage.                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2. Known hypersensitivity to semaglutide or any component of the product.                                                                                                                                                                                                                                   |
| Adverse Effects    | Common Endocrine metabolic: Hypoglycemia (Monotherapy, 1.6% to 3.8%; combination therapy, 6% to 30% ) Gastrointestinal: Abdominal pain (5.7% to 11% ), Constipation (3.1% to 6% ), Diarrhea (8.5% to 10% ), Nausea (11% to 20.3% ), Vomiting (5% to 9.2% ) Serious Endocrine metabolic: Medullary thyroid carcinoma Gastrointestinal: Pancreatitis Immunologic: Hypersensitivity reaction Ophthalmic: Retinopathy due to diabetes mellitus |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                    |

## Rybelsus 7mg

| TAH Drug Code      | [ORYB](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ORYB)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; can be used as monotherapy if patient is intolerant or contraindicated to metformin or be used in combination with other diabetes medications.                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | 3 mg orally QD for 30 days, then increase dose to 7 mg QD. Dose may be increased to 14 mg QD if additional glycemic control is needed after at least 30 days receiving 7-mg dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | [Common] Hypoglycemia (Monotherapy, 1.6-3.8%; combination therapy, 6-30% ), Abdominal pain (Diabetes, 5.7-11% ; weight management, 15-20% ), Constipation (Diabetes, 3.1-6% ; weight management, 6-24% ), Diarrhea (Diabetes, 8.5-10% ; weight management, 22-30% ), Nausea (Diabetes, 11-20.3% ; weight management, 42-44% ), Vomiting (Diabetes, 5-9.2% ; weight management, 24-36% ), Headache (14-17% ) [Serious] Increased heart rate, Medullary thyroid carcinoma, Cholecystitis (0.6-0.8% ), Cholelithiasis (0.4-3.8% ), Pancreatitis, Anaphylaxis, Hypersensitivity reaction, Retinopathy due to diabetes mellitus, Angioedema |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

